{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:40:34Z","timestamp":1793673634537,"version":"4.5.1"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41573-019-0031-6","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T12:03:13Z","timestamp":1563537793000},"page":"707-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":318,"title":["Clinical promise of next-generation complement therapeutics"],"prefix":"10.1038","volume":"18","author":[{"given":"Dimitrios C.","family":"Mastellos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-0233","authenticated-orcid":false,"given":"Daniel","family":"Ricklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-5776","authenticated-orcid":false,"given":"John D.","family":"Lambris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"31_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","volume":"12","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D., Reis, E. S. & Lambris, J. D. Complement in disease: a defence system turning offensive. Nat. Rev. Nephrol. 12, 383\u2013401 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cell.2018.03.013","volume":"173","author":"LC Rankin","year":"2018","unstructured":"Rankin, L. C. & Artis, D. Beyond host defense: emerging functions of the immune system in regulating complex tissue physiology. Cell 173, 554\u2013567 (2018).","journal-title":"Cell"},{"key":"31_CR3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785\u2013797 (2010). This article provides an introductory overview of the mechanisms and functions of complement in tissue homeostasis and host immunosurveillance.","journal-title":"Nat. Immunol."},{"key":"31_CR4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.3858","volume":"18","author":"G Hajishengallis","year":"2017","unstructured":"Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D. & Lambris, J. D. Novel mechanisms and functions of complement. Nat. Immunol. 18, 1288\u20131298 (2017).","journal-title":"Nat. Immunol."},{"key":"31_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12497","volume":"274","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D. & Lambris, J. D. Preformed mediators of defense \u2014 gatekeepers enter the spotlight. Immunol. Rev. 274, 5\u20138 (2016).","journal-title":"Immunol. Rev."},{"key":"31_CR6","first-page":"262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part I \u2014 molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015).","journal-title":"Front. Immunol."},{"key":"31_CR7","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.1195821","volume":"330","author":"F Forneris","year":"2010","unstructured":"Forneris, F. et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330, 1816\u20131820 (2010).","journal-title":"Science"},{"key":"31_CR8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","volume":"37","author":"MC Carroll","year":"2012","unstructured":"Carroll, M. C. & Isenman, D. E. Regulation of humoral immunity by complement. Immunity 37, 199\u2013207 (2012).","journal-title":"Immunity"},{"key":"31_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0168-x","author":"ES Reis","year":"2019","unstructured":"Reis, E. S., Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. New insights into the immune functions of complement. Nat. Rev. Immunol. \nhttps:\/\/doi.org\/10.1038\/s41577-019-0168-x\n\n (2019). This review discusses new insights on how complement-triggered pathways shape innate and adaptive immune responses in convergence with other pattern recognition systems.","journal-title":"Nat. Rev. Immunol."},{"key":"31_CR10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrneph.2017.17","volume":"13","author":"KN Ekdahl","year":"2017","unstructured":"Ekdahl, K. N., Soveri, I., Hilborn, J., Fellstrom, B. & Nilsson, B. Cardiovascular disease in haemodialysis: role of the intravascular innate immune system. Nat. Rev. Nephrol. 13, 285\u2013296 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR11","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.4049\/jimmunol.1203200","volume":"190","author":"D Ricklin","year":"2013","unstructured":"Ricklin, D. & Lambris, J. D. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190, 3839\u20133847 (2013).","journal-title":"J. Immunol."},{"key":"31_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","volume":"274","author":"CQ Schmidt","year":"2016","unstructured":"Schmidt, C. Q., Lambris, J. D. & Ricklin, D. Protection of host cells by complement regulators. Immunol. Rev. 274, 152\u2013171 (2016).","journal-title":"Immunol. Rev."},{"key":"31_CR13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-neuro-061010-113810","volume":"35","author":"AH Stephan","year":"2012","unstructured":"Stephan, A. H., Barres, B. A. & Stevens, B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369\u2013389 (2012). This article provides a comprehensive review of the multifaceted role of complement in shaping central nervous system development and synaptic networks in both health and disease.","journal-title":"Annu. Rev. Neurosci."},{"key":"31_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.smim.2016.03.006","volume":"28","author":"G Hajishengallis","year":"2016","unstructured":"Hajishengallis, G. et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin. Immunol. 28, 285\u2013291 (2016).","journal-title":"Semin. Immunol."},{"key":"31_CR15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.imbio.2015.11.007","volume":"221","author":"CM van Lookeren","year":"2016","unstructured":"van Lookeren, C. M., Strauss, E. C. & Yaspan, B. L. Age-related macular degeneration: complement in action. Immunobiology 221, 733\u2013739 (2016).","journal-title":"Immunobiology"},{"key":"31_CR16","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","volume":"14","author":"BP Morgan","year":"2015","unstructured":"Morgan, B. P. & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14, 857\u2013877 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.smim.2016.07.001","volume":"28","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D. & Lambris, J. D. Complement therapeutics. Semin. Immunol. 28, 205\u2013207 (2016).","journal-title":"Semin. Immunol."},{"key":"31_CR18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2018","unstructured":"Ricklin, D., Mastellos, D. C., Reis, E. S. & Lambris, J. D. The renaissance of complement therapeutics. Nat. Rev. Nephrol. 14, 26\u201347 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.imbio.2016.06.013","volume":"221","author":"DC Mastellos","year":"2016","unstructured":"Mastellos, D. C. et al. From orphan drugs to adopted therapies: advancing C3-targeted intervention to the clinical stage. Immunobiology 221, 1046\u20131057 (2016).","journal-title":"Immunobiology"},{"key":"31_CR20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A. & Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256\u20131264 (2007).","journal-title":"Nat. Biotechnol."},{"key":"31_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0890-8508(87)90022-3","volume":"1","author":"Y Frei","year":"1987","unstructured":"Frei, Y., Lambris, J. D. & Stockinger, B. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol. Cell. Probes 1, 141\u2013149 (1987). This article describes the generation and characterization of the first mouse anti-C5 monoclonal antibodies that formed the basis for the clinical development and subsequent approval of the anti-C5 mAb, eculizumab.","journal-title":"Mol. Cell. Probes"},{"key":"31_CR22","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1073\/pnas.92.19.8955","volume":"92","author":"Y Wang","year":"1995","unstructured":"Wang, Y., Rollins, S. A., Madri, J. A. & Matis, L. A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl Acad. Sci. USA 92, 8955\u20138959 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C. & Fremeaux-Bacchi, V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8, 643\u2013657 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard, J. F. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16, 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"key":"31_CR25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/eci.11.5","volume":"7","author":"L Varga","year":"2011","unstructured":"Varga, L. & Farkas, H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev. Clin. Immunol. 7, 143\u2013153 (2011).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"31_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nri2231","volume":"8","author":"P Gros","year":"2008","unstructured":"Gros, P., Milder, F. J. & Janssen, B. J. Complement driven by conformational changes. Nat. Rev. Immunol. 8, 48\u201358 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"31_CR27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","volume":"136","author":"FG Holz","year":"2018","unstructured":"Holz, F. G. et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 136, 666\u2013677 (2018). This article presents the results from the two multicentre phase III trials that evaluated the efficacy of the FD-targeting antibody lampalizumab in GA patients.","journal-title":"JAMA Ophthalmol."},{"key":"31_CR28","unstructured":"US Food & Drug Administration. FDA approves ravulizumab-cwvz for paroxysmal nocturnal hemoglobinuria. FDA.gov \nhttps:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ravulizumab-cwvz-paroxysmal-nocturnal-hemoglobinuria\n\n (2018)."},{"key":"31_CR29","first-page":"530","volume":"133","author":"JW Lee","year":"2018","unstructured":"Lee, J. W. et al. Ravulizumab (ALXN1210) versus eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133, 530\u2013539 (2018).","journal-title":"Blood"},{"key":"31_CR30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2018","unstructured":"Kulasekararaj, A. G. et al. Ravulizumab (ALXN1210) versus eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133, 540\u2013549 (2018). This clinical study showed that patients with PNH can effectively switch from eculizumab-based therapy to a more patient-compliant, long-acting version of this anti-C5 therapeutic, ravulizumab.","journal-title":"Blood"},{"key":"31_CR31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.smim.2016.06.001","volume":"28","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D. & Lambris, J. D. New milestones ahead in complement-targeted therapy. Semin. Immunol. 28, 208\u2013222 (2016).","journal-title":"Semin. Immunol."},{"key":"31_CR32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nri3225","volume":"12","author":"SH Sacks","year":"2012","unstructured":"Sacks, S. H. & Zhou, W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 12, 431\u2013442 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"31_CR33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.clim.2018.11.010","volume":"198","author":"DC Mastellos","year":"2019","unstructured":"Mastellos, D. C. et al. Taming hemodialysis-induced inflammation: are complement C3 inhibitors a viable option? Clin. Immunol. 198, 102\u2013105 (2019).","journal-title":"Clin. Immunol."},{"key":"31_CR34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molimm.2017.05.014","volume":"89","author":"NM Jager","year":"2017","unstructured":"Jager, N. M., Poppelaars, F., Daha, M. R. & Seelen, M. A. Complement in renal transplantation: the road to translation. Mol. Immunol. 89, 22\u201335 (2017).","journal-title":"Mol. Immunol."},{"key":"31_CR35","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1172\/JCI83000","volume":"126","author":"CA Farrar","year":"2016","unstructured":"Farrar, C. A. et al. Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. J. Clin. Invest. 126, 1911\u20131925 (2016).","journal-title":"J. Clin. Invest."},{"key":"31_CR36","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2018.02023","volume":"9","author":"CL Nauser","year":"2018","unstructured":"Nauser, C. L., Howard, M. C., Fanelli, G., Farrar, C. A. & Sacks, S. Collectin-11 (CL-11) is a major sentinel at epithelial surfaces and key pattern recognition molecule in complement-mediated ischaemic injury. Front. Immunol. 9, 2023 (2018).","journal-title":"Front. Immunol."},{"key":"31_CR37","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.4049\/jimmunol.1201904","volume":"189","author":"A Elvington","year":"2012","unstructured":"Elvington, A. et al. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J. Immunol. 189, 4640\u20134647 (2012).","journal-title":"J. Immunol."},{"key":"31_CR38","doi-asserted-by":"crossref","DOI":"10.1038\/srep31877","volume":"6","author":"J Dob\u00f3","year":"2016","unstructured":"Dob\u00f3, J. et al. MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci. Rep. 6, 31877 (2016). This article describes a fundamental mechanism by which the AP and LP of complement converge and signifies the importance of \u2018bypass\u2019 complement activation modes in health and disease.","journal-title":"Sci. Rep."},{"key":"31_CR39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jss.2004.07.005","volume":"122","author":"RK Chan","year":"2004","unstructured":"Chan, R. K. et al. IgM binding to injured tissue precedes complement activation during skeletal muscle ischemia-reperfusion. J. Surg. Res. 122, 29\u201335 (2004).","journal-title":"J. Surg. Res."},{"key":"31_CR40","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.2353\/ajpath.2010.090276","volume":"176","author":"G Castellano","year":"2010","unstructured":"Castellano, G. et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am. J. Pathol. 176, 1648\u20131659 (2010).","journal-title":"Am. J. Pathol."},{"key":"31_CR41","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02134314\n\n (2018)."},{"key":"31_CR42","first-page":"II274","volume":"110","author":"HL Lazar","year":"2004","unstructured":"Lazar, H. L. et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110, II274\u2013II279 (2004).","journal-title":"Circulation"},{"key":"31_CR43","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT00082121\n\n (2007)."},{"key":"31_CR44","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/14779072.4.5.649","volume":"4","author":"JS Li","year":"2006","unstructured":"Li, J. S., Jaggers, J. & Anderson, P. A. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 4, 649\u2013654 (2006).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"31_CR45","doi-asserted-by":"crossref","first-page":"I83","DOI":"10.1161\/CIRCULATIONAHA.106.677914","volume":"116","author":"HL Lazar","year":"2007","unstructured":"Lazar, H. L. et al. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 116, I83\u2013I88 (2007).","journal-title":"Circulation"},{"key":"31_CR46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/prep.1995.0003","volume":"6","author":"I Dodd","year":"1995","unstructured":"Dodd, I. et al. Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1. Protein Expr. Purif. 6, 727\u2013736 (1995).","journal-title":"Protein Expr. Purif."},{"key":"31_CR47","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-1972-x","volume":"18","author":"T Kassimatis","year":"2017","unstructured":"Kassimatis, T. et al. A double-blind randomised controlled investigation into the efficacy of mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial. Trials 18, 255 (2017).","journal-title":"Trials"},{"key":"31_CR48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/imr.12470","volume":"274","author":"A Alawieh","year":"2016","unstructured":"Alawieh, A. & Tomlinson, S. Injury site-specific targeting of complement inhibitors for treating stroke. Immunol. Rev. 274, 270\u2013280 (2016).","journal-title":"Immunol. Rev."},{"key":"31_CR49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4614-4118-2_9","volume":"735","author":"VM Holers","year":"2013","unstructured":"Holers, V. M., Rohrer, B. & Tomlinson, S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 735, 137\u2013154 (2013).","journal-title":"Adv. Exp. Med. Biol."},{"key":"31_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12974-015-0464-8","volume":"12","author":"A Alawieh","year":"2015","unstructured":"Alawieh, A. et al. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J. Neuroinflamm. 12, 247 (2015).","journal-title":"J. Neuroinflamm."},{"key":"31_CR51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrd.2018.98","volume":"17","author":"S Crunkhorn","year":"2018","unstructured":"Crunkhorn, S. Stroke: opening the therapeutic window. Nat. Rev. Drug Discov. 17, 467 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31_CR52","doi-asserted-by":"crossref","first-page":"eaao6459","DOI":"10.1126\/scitranslmed.aao6459","volume":"10","author":"A Alawieh","year":"2018","unstructured":"Alawieh, A., Langley, E. F. & Tomlinson, S. Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice. Sci. Transl Med. 10, eaao6459 (2018). This study underscores the translational potential of targeted complement inhibition in ischaemic stroke.","journal-title":"Sci. Transl Med."},{"key":"31_CR53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12974-016-0684-6","volume":"13","author":"F Orsini","year":"2016","unstructured":"Orsini, F. et al. Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1. J. Neuroinflamm. 13, 213 (2016).","journal-title":"J. Neuroinflamm."},{"key":"31_CR54","unstructured":"Omeros Corporation. FDA grants breakthrough therapy designation to Omeros\u2019 MASP-2 inhibitor OMS721 for the treatment of IgA nephropathy. Business Wire \nhttps:\/\/www.businesswire.com\/news\/home\/20170613005978\/en\/FDA-Grants-Breakthrough-Therapy-Designation-Omeros\u2019-MASP-2\n\n (2019)."},{"key":"31_CR55","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","volume":"379","author":"A Loupy","year":"2018","unstructured":"Loupy, A. & Lefaucheur, C. Antibody-mediated rejection of solid-organ allografts. N. Engl. J. Med. 379, 1150\u20131160 (2018).","journal-title":"N. Engl. J. Med."},{"key":"31_CR56","unstructured":"Biglarnia, A.-R., Huber-Lang, M., Mohlin, C., Ekdahl, K. N. & Nilsson, B. The multifaceted role of complement in kidney transplantation. Nat. Rev. Nephrol. 14, 767\u2013781 (2018)."},{"key":"31_CR57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrneph.2012.212","volume":"8","author":"MD Stegall","year":"2012","unstructured":"Stegall, M. D., Chedid, M. F. & Cornell, L. D. The role of complement in antibody-mediated rejection in kidney transplantation. Nat. Rev. Nephrol. 8, 670\u2013678 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR58","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41581-018-0039-x","volume":"14","author":"RA Montgomery","year":"2018","unstructured":"Montgomery, R. A., Tatapudi, V. S., Leffell, M. S. & Zachary, A. A. HLA in transplantation. Nat. Rev. Nephrol. 14, 558\u2013570 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40472-017-0148-7","volume":"4","author":"VS Tatapudi","year":"2017","unstructured":"Tatapudi, V. S. & Montgomery, R. A. Pharmacologic complement inhibition in clinical transplantation. Curr. Transplant. Rep. 4, 91\u2013100 (2017).","journal-title":"Curr. Transplant. Rep."},{"key":"31_CR60","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","volume":"29","author":"C Lefaucheur","year":"2018","unstructured":"Lefaucheur, C. et al. Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment. J. Am. Soc. Nephrol. 29, 620\u2013635 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"31_CR61","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","volume":"11","author":"MD Stegall","year":"2011","unstructured":"Stegall, M. D. et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11, 2405\u20132413 (2011).","journal-title":"Am. J. Transplant."},{"key":"31_CR62","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","volume":"16","author":"RA Montgomery","year":"2016","unstructured":"Montgomery, R. A. et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am. J. Transplant. 16, 3468\u20133478 (2016).","journal-title":"Am. J. Transplant."},{"key":"31_CR63","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","volume":"16","author":"D Viglietti","year":"2016","unstructured":"Viglietti, D. et al. C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study. Am. J. Transplant. 16, 1596\u20131603 (2016).","journal-title":"Am. J. Transplant."},{"key":"31_CR64","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02547220\n\n (2019)."},{"key":"31_CR65","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.imbio.2015.06.012","volume":"221","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D. & Lambris, J. D. Therapeutic control of complement activation at the level of the central component C3. Immunobiology 221, 740\u2013746 (2016).","journal-title":"Immunobiology"},{"key":"31_CR66","unstructured":"Amyndas Pharmaceuticals. Our focus. Amyndas Pharmaceuticals \nhttp:\/\/amyndas.com\/research-focus\/\n\n (2019)."},{"key":"31_CR67","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.it.2012.09.004","volume":"34","author":"M Bosmann","year":"2013","unstructured":"Bosmann, M. & Ward, P. A. The inflammatory response in sepsis. Trends Immunol. 34, 129\u2013136 (2013).","journal-title":"Trends Immunol."},{"key":"31_CR68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.smim.2018.02.004","volume":"37","author":"R Halbgebauer","year":"2018","unstructured":"Halbgebauer, R., Schmidt, C. Q., Karsten, C. M., Ignatius, A. & Huber-Lang, M. Janus face of complement-driven neutrophil activation during sepsis. Semin. Immunol. 37, 12\u201320 (2018).","journal-title":"Semin. Immunol."},{"key":"31_CR69","first-page":"78","volume":"51","author":"M van Griensven","year":"2018","unstructured":"van Griensven, M. et al. Protective effects of the complement inhibitor compstatin Cp40 in hemorrhagic shock. J. Immunol. 51, 78\u201387 (2018).","journal-title":"J. Immunol."},{"key":"31_CR70","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1182\/blood-2010-02-269746","volume":"116","author":"R Silasi-Mansat","year":"2010","unstructured":"Silasi-Mansat, R. et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116, 1002\u20131010 (2010).","journal-title":"Blood"},{"key":"31_CR71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4614-4118-2_8","volume":"735","author":"OL Brekke","year":"2013","unstructured":"Brekke, O. L. et al. The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood. Adv. Exp. Med. Biol. 735, 123\u2013136 (2013).","journal-title":"Adv. Exp. Med. Biol."},{"key":"31_CR72","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.4049\/jimmunol.1400341","volume":"192","author":"M Huber-Lang","year":"2014","unstructured":"Huber-Lang, M. et al. Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J. Immunol. 192, 5324\u20135331 (2014).","journal-title":"J. Immunol."},{"key":"31_CR73","doi-asserted-by":"crossref","first-page":"E6390","DOI":"10.1073\/pnas.1706818114","volume":"114","author":"RS Keshari","year":"2017","unstructured":"Keshari, R. S. et al. Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proc. Natl Acad. Sci. USA 114, E6390\u2013E6399 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR74","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02246595\n\n (2016)."},{"key":"31_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03487276\n\n (2018)."},{"key":"31_CR76","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01766414\n\n (2014)."},{"key":"31_CR77","unstructured":"Aridis Pharmaceuticals. AR-101 (AerumabTM): fully human mAb against Pseudomonas aeruginosa LPS serotype O11. Aridis Pharmaceuticals \nhttps:\/\/aridispharma.com\/ar-101\/\n\n (2019)."},{"key":"31_CR78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fimmu.2018.00071","volume":"9","author":"F Poppelaars","year":"2018","unstructured":"Poppelaars, F. et al. The complement system in dialysis: a forgotten story? Front. Immunol. 9, 71 (2018).","journal-title":"Front. Immunol."},{"key":"31_CR79","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.imbio.2012.07.012","volume":"217","author":"RA Deangelis","year":"2012","unstructured":"Deangelis, R. A., Reis, E. S., Ricklin, D. & Lambris, J. D. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 217, 1097\u20131105 (2012).","journal-title":"Immunobiology"},{"key":"31_CR80","first-page":"2","volume":"Suppl. 1","author":"D Santoro","year":"2013","unstructured":"Santoro, D. et al. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin. Nephrol. 79 (Suppl. 1), 2\u201311 (2013).","journal-title":"Clin. Nephrol. 79"},{"key":"31_CR81","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3389\/fimmu.2018.02070","volume":"9","author":"F Poppelaars","year":"2018","unstructured":"Poppelaars, F. et al. Intradialytic complement activation precedes the development of cardiovascular events in hemodialysis patients. Front. Immunol. 9, 2070 (2018). This study links HD-induced complement activation with an increased risk of cardiovascular events in HD patients.","journal-title":"Front. Immunol."},{"key":"31_CR82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.imbio.2014.10.026","volume":"220","author":"ES Reis","year":"2015","unstructured":"Reis, E. S. et al. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 220, 476\u2013482 (2015).","journal-title":"Immunobiology"},{"key":"31_CR83","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136\u2013147 (2013).","journal-title":"Chem. Biol. Drug Des."},{"key":"31_CR84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrd1133","volume":"2","author":"BL Bray","year":"2003","unstructured":"Bray, B. L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2, 587\u2013593 (2003). This article points to the potential for more affordable biological therapies exploiting the large-scale chemical synthesis of therapeutic peptides.","journal-title":"Nat. Rev. Drug Discov."},{"key":"31_CR85","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41579-018-0089-x","volume":"16","author":"RJ Lamont","year":"2018","unstructured":"Lamont, R. J., Koo, H. & Hajishengallis, G. The oral microbiota: dynamic communities and host interactions. Nat. Rev. Microbiol. 16, 745\u2013759 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"31_CR86","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/0022034512457373","volume":"91","author":"PI Eke","year":"2012","unstructured":"Eke, P. I., Dye, B. A., Wei, L., Thornton-Evans, G. O. & Genco, R. J. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J. Dent. Res. 91, 914\u2013920 (2012).","journal-title":"J. Dent. Res."},{"key":"31_CR87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nri3785","volume":"15","author":"G Hajishengallis","year":"2015","unstructured":"Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 15, 30\u201344 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"31_CR88","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.it.2010.01.002","volume":"31","author":"G Hajishengallis","year":"2010","unstructured":"Hajishengallis, G. & Lambris, J. D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 31, 154\u2013163 (2010).","journal-title":"Trends Immunol."},{"key":"31_CR89","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/jcpe.12507","volume":"43","author":"T Maekawa","year":"2016","unstructured":"Maekawa, T. et al. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J. Clin. Periodontol. 43, 238\u2013249 (2016).","journal-title":"J. Clin. Periodontol."},{"key":"31_CR90","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.omtm.2017.08.001","volume":"6","author":"T Kajikawa","year":"2017","unstructured":"Kajikawa, T. et al. Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates. Mol. Ther. Methods Clin. Dev. 6, 207\u2013215 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"31_CR91","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/17474086.2014.953926","volume":"7","author":"DC Mastellos","year":"2014","unstructured":"Mastellos, D. C., Ricklin, D., Yancopoulou, D., Risitano, A. & Lambris, J. D. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev. Hematol. 7, 583\u2013598 (2014).","journal-title":"Expert Rev. Hematol."},{"key":"31_CR92","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.25016","volume":"93","author":"AM Risitano","year":"2018","unstructured":"Risitano, A. M. & Marotta, S. Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 93, 564\u2013577 (2018).","journal-title":"Am. J. Hematol."},{"key":"31_CR93","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura, J. et al. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 370, 632\u2013639 (2014).","journal-title":"N. Engl. J. Med."},{"key":"31_CR94","unstructured":"Armstrong, M. Samsung joins Soliris biosimilar quest. Evaluate \nhttp:\/\/www.evaluate.com\/vantage\/articles\/news\/snippets\/samsung-joins-soliris-biosimilar-quest\n\n (2019)."},{"key":"31_CR95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","volume":"55","author":"DC Mastellos","year":"2018","unstructured":"Mastellos, D. C., Reis, E. S., Yancopoulou, D., Risitano, A. M. & Lambris, J. D. Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 55, 167\u2013175 (2018).","journal-title":"Semin. Hematol."},{"key":"31_CR96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nri.2017.97","volume":"18","author":"ES Reis","year":"2018","unstructured":"Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A. & Lambris, J. D. Complement in cancer: untangling an intricate relationship. Nat. Rev. Immunol. 18, 5\u201318 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"31_CR97","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1586\/1744666X.2015.1074039","volume":"11","author":"BP Morgan","year":"2015","unstructured":"Morgan, B. P. The role of complement in neurological and neuropsychiatric diseases. Expert Rev. Clin. Immunol. 11, 1109\u20131119 (2015).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"31_CR98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith, R. J. H. et al. C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease. Nat. Rev. Nephrol. 15, 129\u2013143 (2019). A comprehensive review discussing pathophysiological aspects, patient stratification criteria and therapeutic options for the complement-mediated renal disorder C3G.","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2018.04.003","volume":"55","author":"S Jodele","year":"2018","unstructured":"Jodele, S. Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies. Semin. Hematol. 55, 159\u2013166 (2018).","journal-title":"Semin. Hematol."},{"key":"31_CR100","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233\u20131243 (2006).","journal-title":"N. Engl. J. Med."},{"key":"31_CR101","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen, P. et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 162, 62\u201373 (2013).","journal-title":"Br. J. Haematol."},{"key":"31_CR102","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","volume":"113","author":"AM Risitano","year":"2009","unstructured":"Risitano, A. M. et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113, 4094\u20134100 (2009).","journal-title":"Blood"},{"key":"31_CR103","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","volume":"129","author":"MJ Harder","year":"2017","unstructured":"Harder, M. J. et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 129, 970\u2013980 (2017).","journal-title":"Blood"},{"key":"31_CR104","unstructured":"Elgin, B., Bloomfield, D. & Chen, C. When the patient is a gold mine: the trouble with rare-disease drugs. Bloomberg \nhttps:\/\/www.bloomberg.com\/news\/features\/2017-05-24\/when-the-patient-is-a-gold-mine-the-trouble-with-rare-disease-drugs\n\n (2019). This is a popular article highlighting the significant economic burden associated with the currently approved complement-based therapy in the clinic."},{"key":"31_CR105","unstructured":"America\u2019s Health Insurance Plans. High-priced drugs: estimates of annual per-patient expenditures for 150 specialty medications. AHIP \nhttps:\/\/www.ahip.org\/report-high-priced-drugs-expenditures\/\n\n (2016)."},{"key":"31_CR106","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.imbio.2016.06.078","volume":"221","author":"D Sheridan","year":"2016","unstructured":"Sheridan, D. et al. Design and preclinical characterization of ALXN1210: a next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action. Immunobiology 221, 1158 (2016).","journal-title":"Immunobiology"},{"key":"31_CR107","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","volume":"2","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th, A. et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies. Blood Adv. 2, 2176\u20132185 (2018).","journal-title":"Blood Adv."},{"key":"31_CR108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01087-7","volume":"7","author":"T Fukuzawa","year":"2017","unstructured":"Fukuzawa, T. et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci. Rep. 7, 1080 (2017).","journal-title":"Sci. Rep."},{"key":"31_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02534909\n\n (2019)."},{"key":"31_CR110","unstructured":"Adis Insight. Pozelimab \u2014 Regeneron Pharmaceuticals. Adis Insight \nhttp:\/\/adisinsight.springer.com\/drugs\/800049599\n\n (2018)."},{"key":"31_CR111","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1182\/blood-2017-03-775759","volume":"130","author":"A Hill","year":"2017","unstructured":"Hill, A., Weston-Davies, W. H., Nunn, M., Robak, T. & Windyga, J. Coversin, a novel C5 complement inhibitor, is safe and effective in the treatment of PNH: results of a phase II clinical trial. Blood 130, 4747 (2017).","journal-title":"Blood"},{"key":"31_CR112","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03427060\n\n (2018)."},{"key":"31_CR113","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2018.125","volume":"17","author":"C Morrison","year":"2018","unstructured":"Morrison, C. Constrained peptides\u2019 time to shine? Nat. Rev. Drug Discov. 17, 531\u2013533 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31_CR114","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood.V126.23.939.939","volume":"126","author":"A Ricardo","year":"2015","unstructured":"Ricardo, A. et al. Preclinical evaluation of RA101495, a potent cyclic peptide inhibitor of C5 for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 126, 939 (2015).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"31_CR115","first-page":"415","volume":"101","author":"JM Johnston","year":"2016","unstructured":"Johnston, J. M. et al. Phase 1 multiple-dose clinical study of RA101495, a subcutaneously administered synthetic macrocyclic peptide inhibitor of complement C5 for treatment of paroxysmal nocturnal hemoglobinuria [abstract LB2249]. Haematologica 101 (Suppl. 1), 415 (2016).","journal-title":"Haematologica"},{"key":"31_CR116","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03078582\n\n (2018)."},{"key":"31_CR117","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood.V128.22.3891.3891","volume":"128","author":"A Hill","year":"2016","unstructured":"Hill, A. et al. A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: preliminary phase 1\/2 study results in patients with PNH. Blood 128, 3891 (2016).","journal-title":"Blood"},{"key":"31_CR118","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/eci.12419","volume":"45","author":"DC Mastellos","year":"2015","unstructured":"Mastellos, D. C. et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur. J. Clin. Invest. 45, 423\u2013440 (2015).","journal-title":"Eur. J. Clin. Invest."},{"key":"31_CR119","first-page":"273","volume":"632","author":"D Ricklin","year":"2008","unstructured":"Ricklin, D. & Lambris, J. D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 632, 273\u2013292 (2008).","journal-title":"Adv. Exp. Med. Biol."},{"key":"31_CR120","doi-asserted-by":"crossref","first-page":"29241","DOI":"10.1074\/jbc.M704587200","volume":"282","author":"BJ Janssen","year":"2007","unstructured":"Janssen, B. J., Halff, E. F., Lambris, J. D. & Gros, P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282, 29241\u201329247 (2007).","journal-title":"J. Biol. Chem."},{"key":"31_CR121","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","volume":"123","author":"AM Risitano","year":"2014","unstructured":"Risitano, A. M. et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123, 2094\u20132101 (2014). This is the first study demonstrating proof of efficacy and translational potential for the C3 inhibitory peptides, termed compstatins, in\u00a0treating PNH.","journal-title":"Blood"},{"key":"31_CR122","unstructured":"Apellis Pharmaceuticals. Our focus. Apellis Pharmaceuticals \nhttp:\/\/apellis.com\/focus-science.html\n\n (2019)."},{"key":"31_CR123","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02264639\n\n (2018)."},{"key":"31_CR124","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02588833\n\n (2019)."},{"key":"31_CR125","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03500549\n\n (2019)."},{"key":"31_CR126","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03531255\n\n (2018)."},{"key":"31_CR127","unstructured":"Amyndas Pharmaceuticals. Clinical trials. Amyndas Pharmaceuticals \nhttp:\/\/amyndas.com\/clinical-trials\/\n\n (2019)."},{"key":"31_CR128","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1021\/acs.jmedchem.8b00560","volume":"61","author":"N Berger","year":"2018","unstructured":"Berger, N. et al. New analogs of the complement C3 inhibitor compstatin with increased solubility and improved pharmacokinetic profile. J. Med. Chem. 61, 6153\u20136162 (2018).","journal-title":"J. Med. Chem."},{"key":"31_CR129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","volume":"102","author":"CL Harris","year":"2018","unstructured":"Harris, C. L., Pouw, R. B., Kavanagh, D., Sun, R. & Ricklin, D. Developments in anti-complement therapy; from disease to clinical trial. Mol. Immunol. 102, 89\u2013119 (2018). This review discusses the pathophysiological basis of complement-mediated diseases, presenting a detailed description of ongoing clinical trials in various indications.","journal-title":"Mol. Immunol."},{"key":"31_CR130","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart, A. et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc. Natl Acad. Sci. USA 116, 7926\u20137931 (2019). This study describes the rational design and preclinical evaluation of an orally available FB inhibitor with clinical potential for the treatment of PNH and other AP-mediated complement disorders.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03439839\n\n (2019)."},{"key":"31_CR132","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2016.153312","volume":"102","author":"X Yuan","year":"2017","unstructured":"Yuan, X. et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 102, 466\u2013475 (2017). This study indicates the efficacy and clinical potential of orally available FD inhibitors for the treatment of PNH and other AP-mediated complement disorders.","journal-title":"Haematologica"},{"key":"31_CR133","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03053102\n\n (2018)."},{"key":"31_CR134","unstructured":"Achillion Pharmaceuticals. Achillion reports positive interim data for ACH-4471 phase 2 trials and provides clinical development strategy update. GlobeNewswire \nhttps:\/\/globenewswire.com\/news-release\/2018\/12\/17\/1668298\/0\/en\/Achillion-Reports-Positive-Interim-Data-for-ACH-4471-Phase-2-Trials-and-Provides-Clinical-Development-Strategy-Update.html\n\n (2019)."},{"key":"31_CR135","unstructured":"Lambris, J. D., Qu, H. & Ricklin, D. Compstatin analogs with improved pharmacokinetic properties. US Patent 9630992B2 (2019)."},{"key":"31_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03347422\n\n (2019)."},{"key":"31_CR137","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03347396\n\n (2019)."},{"key":"31_CR138","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03226678\n\n (2019)."},{"key":"31_CR139","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI116706","volume":"92","author":"RH Wang","year":"1993","unstructured":"Wang, R. H., Phillips, G., Medof, M. E. & Mold, C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J. Clin. Invest. 92, 1326\u20131335 (1993).","journal-title":"J. Clin. Invest."},{"key":"31_CR140","doi-asserted-by":"crossref","first-page":"96910","DOI":"10.1172\/jci.insight.96910","volume":"3","author":"NS Merle","year":"2018","unstructured":"Merle, N. S. et al. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight 3, 96910 (2018). This study revealed the complement-activating properties of cell-free haem and points to a new mechanism that amplifies complement-mediated injury during intravascular haemolysis.","journal-title":"JCI Insight"},{"key":"31_CR141","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2018.194670","volume":"103","author":"S Chonat","year":"2018","unstructured":"Chonat, S. et al. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 103, e483\u2013e485 (2018).","journal-title":"Haematologica"},{"key":"31_CR142","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","volume":"104","author":"E Lombardi","year":"2019","unstructured":"Lombardi, E. et al. Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule. Haematologica 104, 919\u2013928 (2019).","journal-title":"Haematologica"},{"key":"31_CR143","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.molmed.2014.01.001","volume":"20","author":"S Biryukov","year":"2014","unstructured":"Biryukov, S. & Stoute, J. A. Complement activation in malaria: friend or foe? Trends Mol. Med. 20, 293\u2013301 (2014).","journal-title":"Trends Mol. Med."},{"key":"31_CR144","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clim.2016.08.017","volume":"171","author":"MA Lindorfer","year":"2016","unstructured":"Lindorfer, M. A. et al. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: implications for treatment of malarial anemia. Clin. Immunol. 171, 32\u201335 (2016).","journal-title":"Clin. Immunol."},{"key":"31_CR145","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1073\/pnas.1814797116","volume":"116","author":"NS Merle","year":"2019","unstructured":"Merle, N. S. et al. P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4\/heme-dependent manner. Proc. Natl Acad. Sci. USA 116, 6280\u20136285 (2019). This study illustrates the therapeutic potential of targeting P-selectin on endothelial surfaces as a means of blocking complement deposition and attenuating tissue injury in various haemolytic disorders.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","volume":"15","author":"N Jourde-Chiche","year":"2019","unstructured":"Jourde-Chiche, N. et al. Endothelium structure and function in kidney health and disease. Nat. Rev. Nephrol. 15, 87\u2013108 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR147","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0034-1376334","volume":"40","author":"X Xiao","year":"2014","unstructured":"Xiao, X., Pickering, M. C. & Smith, R. J. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin. Thromb. Hemost. 40, 465\u2013471 (2014).","journal-title":"Semin. Thromb. Hemost."},{"key":"31_CR148","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2016.99","volume":"12","author":"MA Durey","year":"2016","unstructured":"Durey, M. A., Sinha, A., Togarsimalemath, S. K. & Bagga, A. Anti-complement-factor H-associated glomerulopathies. Nat. Rev. Nephrol. 12, 563\u2013578 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"31_CR149","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0034-1375701","volume":"40","author":"S Sethi","year":"2014","unstructured":"Sethi, S. & Fervenza, F. C. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin. Thromb. Hemost. 40, 416\u2013421 (2014).","journal-title":"Semin. Thromb. Hemost."},{"key":"31_CR150","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1681\/ASN.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu, F. et al. Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 29, 2809\u20132819 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"31_CR151","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","volume":"122","author":"M Frimat","year":"2013","unstructured":"Frimat, M. et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122, 282\u2013292 (2013).","journal-title":"Blood"},{"key":"31_CR152","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","volume":"93","author":"A Huerta","year":"2018","unstructured":"Huerta, A. et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 93, 450\u2013459 (2018).","journal-title":"Kidney Int."},{"key":"31_CR153","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"31_CR154","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003573","volume":"3","author":"J Rathbone","year":"2013","unstructured":"Rathbone, J. et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 3, e003573 (2013).","journal-title":"BMJ Open"},{"key":"31_CR155","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131219\n\n (2018)."},{"key":"31_CR156","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02949128\n\n (2019)."},{"key":"31_CR157","unstructured":"Alexion Pharmaceuticals. Alexion announces positive top-line results from phase 3 study of ULTOMIRIS\u2122 (Ravulizumab-Cwvz) in complement inhibitor-na\u00efve patients with atypical hemolytic uremic syndrome (aHUS). Alexion Newsroom \nhttps:\/\/news.alexion.com\/press-release\/product-news\/alexion-announces-positive-top-line-results-phase-3-study-ultomiris-ravul\n\n (2019)."},{"key":"31_CR158","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02464891\n\n (2017)."},{"key":"31_CR159","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03205995\n\n (2018)."},{"key":"31_CR160","doi-asserted-by":"crossref","first-page":"99128","DOI":"10.1172\/jci.insight.99128","volume":"3","author":"AJ Vaught","year":"2018","unstructured":"Vaught, A. J. et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 3, 99128 (2018).","journal-title":"JCI Insight"},{"key":"31_CR161","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","volume":"96","author":"J Qi","year":"2017","unstructured":"Qi, J. et al. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Ann. Hematol. 96, 1849\u20131855 (2017).","journal-title":"Ann. Hematol."},{"key":"31_CR162","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/bloodadvances.2017008250","volume":"1","author":"SJ Rotz","year":"2017","unstructured":"Rotz, S. J. et al. In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Adv. 1, 1632\u20131634 (2017).","journal-title":"Blood Adv."},{"key":"31_CR163","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03518203\n\n (2019)."},{"key":"31_CR164","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/bloodadvances.2016002832","volume":"1","author":"THJ Goodship","year":"2017","unstructured":"Goodship, T. H. J. et al. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 1, 1254\u20131258 (2017).","journal-title":"Blood Adv."},{"key":"31_CR165","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02222545\n\n (2019)."},{"key":"31_CR166","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02355782\n\n (2015)."},{"key":"31_CR167","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering, M. C. et al. C3 glomerulopathy: consensus report. Kidney Int. 84, 1079\u20131089 (2013).","journal-title":"Kidney Int."},{"key":"31_CR168","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","volume":"82","author":"S Sethi","year":"2012","unstructured":"Sethi, S. et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 82, 465\u2013473 (2012).","journal-title":"Kidney Int."},{"key":"31_CR169","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais, A. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454\u2013464 (2012).","journal-title":"Kidney Int."},{"key":"31_CR170","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","volume":"376","author":"DP Gale","year":"2010","unstructured":"Gale, D. P. et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376, 794\u2013801 (2010).","journal-title":"Lancet"},{"key":"31_CR171","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu, F. et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J. Am. Soc. Nephrol. 27, 1245\u20131253 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"31_CR172","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.smim.2016.06.002","volume":"28","author":"CM Nester","year":"2016","unstructured":"Nester, C. M. & Smith, R. J. Complement inhibition in C3 glomerulopathy. Semin. Immunol. 28, 241\u2013249 (2016).","journal-title":"Semin. Immunol."},{"key":"31_CR173","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback, A. S. et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 7, 748\u2013756 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"31_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03301467\n\n (2018)."},{"key":"31_CR175","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne, D. R. W. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756\u20132767 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"31_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01363388\n\n (2013)."},{"key":"31_CR177","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02682407\n\n (2018)."},{"key":"31_CR178","unstructured":"Achillion Pharmaceuticals. Advancing factor D inhibition into late-stage clinical development. Achillion Pharmaceuticals \nhttp:\/\/www.achillion.com\/pipeline\/\n\n (2019)."},{"key":"31_CR179","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","volume":"38","author":"DC Mastellos","year":"2017","unstructured":"Mastellos, D. C., Reis, E. S., Ricklin, D., Smith, R. J. & Lambris, J. D. Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery. Trends Immunol. 38, 383\u2013394 (2017).","journal-title":"Trends Immunol."},{"key":"31_CR180","unstructured":"Apellis Pharmaceuticals. Apellis Pharmaceuticals\u2019 APL-2 receives orphan drug designation from the FDA for the treatment of C3 glomerulopathy. Apellis Pharmaceuticals \nhttp:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-pharmaceuticals-apl-2-receives-orphan-drug-designation\n\n (2019)."},{"key":"31_CR181","unstructured":"Amyndas Pharmaceuticals. Press release: Amyndas\u2019 lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy. Amyndas Pharmaceuticals \nhttp:\/\/amyndas.com\/press-release-amyndas-lead-candidate-amy-101-receives-orphan-drug-status-from-the-fda-and-the-ema-for-the-treatment-of-c3-glomerulopathy\/\n\n (2019)."},{"key":"31_CR182","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03453619\n\n (2019)."},{"key":"31_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03316521\n\n (2018)."},{"key":"31_CR184","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semnephrol.2017.05.018","volume":"37","author":"M Noris","year":"2017","unstructured":"Noris, M. & Remuzzi, G. Genetics of immune-mediated glomerular diseases: focus on complement. Semin. Nephrol. 37, 447\u2013463 (2017).","journal-title":"Semin. Nephrol."},{"key":"31_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03608033\n\n (2019)."},{"key":"31_CR186","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2017.05.028","volume":"89","author":"C Mohlin","year":"2017","unstructured":"Mohlin, C., Sandholm, K., Ekdahl, K. N. & Nilsson, B. The link between morphology and complement in ocular disease. Mol. Immunol. 89, 84\u201399 (2017).","journal-title":"Mol. Immunol."},{"key":"31_CR187","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","volume":"102","author":"GS Hageman","year":"2005","unstructured":"Hageman, G. S. et al. A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA 102, 7227\u20137232 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR188","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","volume":"308","author":"JL Haines","year":"2005","unstructured":"Haines, J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419\u2013421 (2005).","journal-title":"Science"},{"key":"31_CR189","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","volume":"308","author":"RJ Klein","year":"2005","unstructured":"Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385\u2013389 (2005).","journal-title":"Science"},{"key":"31_CR190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molimm.2014.06.032","volume":"61","author":"EC Schramm","year":"2014","unstructured":"Schramm, E. C. et al. Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol. Immunol. 61, 118\u2013125 (2014).","journal-title":"Mol. Immunol."},{"key":"31_CR191","doi-asserted-by":"crossref","first-page":"12886","DOI":"10.1074\/jbc.M112.345082","volume":"287","author":"KJ Katschke Jr.","year":"2012","unstructured":"Katschke Jr., K. J. et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 287, 12886\u201312892 (2012).","journal-title":"J. Biol. Chem."},{"key":"31_CR192","doi-asserted-by":"crossref","first-page":"eaaf1443","DOI":"10.1126\/scitranslmed.aaf1443","volume":"9","author":"BL Yaspan","year":"2017","unstructured":"Yaspan, B. L. et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci. Transl Med. 9, eaaf1443 (2017).","journal-title":"Sci. Transl Med."},{"key":"31_CR193","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000484257","volume":"10","author":"S Irmscher","year":"2017","unstructured":"Irmscher, S. et al. Kallikrein cleaves C3 and activates complement. J. Innate Immun. 10, 94\u2013105 (2017).","journal-title":"J. Innate Immun."},{"key":"31_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01603043\n\n (2014)."},{"key":"31_CR195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4419-5635-4_9","volume":"703","author":"ZL Chi","year":"2010","unstructured":"Chi, Z. L., Yoshida, T., Lambris, J. D. & Iwata, T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 703, 127\u2013135 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"31_CR196","unstructured":"Apellis Pharmaceuticals. Apellis Pharmaceuticals announces 18-month results of phase 2 study (FILLY) of APL-2 in geographic atrophy. Apellis Pharmaceuticals \nhttp:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-pharmaceuticals-announces-18-month-results-phase-2-study\n\n (2019)."},{"key":"31_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525613\n\n (2018)."},{"key":"31_CR198","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.drudis.2014.06.002","volume":"19","author":"A Baumann","year":"2014","unstructured":"Baumann, A., Tuerck, D., Prabhu, S., Dickmann, L. & Sims, J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov. Today 19, 1623\u20131631 (2014).","journal-title":"Drug Discov. Today"},{"key":"31_CR199","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1074\/jbc.M110.204701","volume":"286","author":"VV Lyzogubov","year":"2011","unstructured":"Lyzogubov, V. V., Tytarenko, R. G., Liu, J., Bora, N. S. & Bora, P. S. Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization. J. Biol. Chem. 286, 16229\u201316237 (2011).","journal-title":"J. Biol. Chem."},{"key":"31_CR200","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/ATVBAHA.114.304927","volume":"35","author":"C-C Ruan","year":"2015","unstructured":"Ruan, C.-C. et al. Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate-salt mice. Arterioscler. Thromb. Vasc. Biol. 35, 598\u2013606 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"31_CR201","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1440-1827.2011.02695.x","volume":"61","author":"X Cao","year":"2011","unstructured":"Cao, X. et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol. Int. 61, 528\u2013535 (2011).","journal-title":"Pathol. Int."},{"key":"31_CR202","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.imbio.2012.06.003","volume":"218","author":"H Qu","year":"2013","unstructured":"Qu, H. et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218, 496\u2013505 (2013).","journal-title":"Immunobiology"},{"key":"31_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03446144\n\n (2018)."},{"key":"31_CR204","first-page":"561","volume":"23","author":"TR Grossman","year":"2017","unstructured":"Grossman, T. R. et al. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide. Mol. Vis. 23, 561\u2013571 (2017).","journal-title":"Mol. Vis."},{"key":"31_CR205","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1167\/iovs.14-15910","volume":"56","author":"G Schnabolk","year":"2015","unstructured":"Schnabolk, G. et al. Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 56, 1850\u20131863 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"31_CR206","volume":"8","author":"KJ Katschke","year":"2018","unstructured":"Katschke, K. J. et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Sci. Rep. 8, 7348 (2018).","journal-title":"Sci. Rep."},{"key":"31_CR207","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT00935883\n\n (2017)."},{"key":"31_CR208","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01527500\n\n (2019)."},{"key":"31_CR209","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02686658\n\n (2018)."},{"key":"31_CR210","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","volume":"46","author":"M Botto","year":"2009","unstructured":"Botto, M. et al. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 46, 2774\u20132783 (2009).","journal-title":"Mol. Immunol."},{"key":"31_CR211","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clim.2018.09.004","volume":"197","author":"ES Reis","year":"2018","unstructured":"Reis, E. S. et al. Safety profile after prolonged C3 inhibition. Clin. Immunol. 197, 96\u2013106 (2018).","journal-title":"Clin. Immunol."},{"key":"31_CR212","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","volume":"130","author":"M Konar","year":"2017","unstructured":"Konar, M. & Granoff, D. M. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 130, 891\u2013899 (2017).","journal-title":"Blood"},{"key":"31_CR213","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","volume":"33","author":"CL Harris","year":"2012","unstructured":"Harris, C. L., Heurich, M., Rodriguez de, C. S. & Morgan, B. P. The complotype: dictating risk for inflammation and infection. Trends Immunol. 33, 513\u2013521 (2012).","journal-title":"Trends Immunol."},{"key":"31_CR214","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","volume":"9","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa, M. et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front. Immunol. 9, 2664 (2018). This study illustrates the importance of assessing the impact of gender-specific and age-specific differences on complement activity and protein levels among healthy individuals.","journal-title":"Front. Immunol."},{"key":"31_CR215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2016.06.004","volume":"76","author":"J Kotimaa","year":"2016","unstructured":"Kotimaa, J. et al. Sex matters: systemic complement activity of female C57BL\/6J and BALB\/cJ mice is limited by serum terminal pathway components. Mol. Immunol. 76, 13\u201321 (2016).","journal-title":"Mol. Immunol."},{"key":"31_CR216","doi-asserted-by":"crossref","first-page":"962702","DOI":"10.1155\/2012\/962702","volume":"2012","author":"B Nilsson","year":"2012","unstructured":"Nilsson, B. & Ekdahl, K. N. Complement diagnostics: concepts, indications, and practical guidelines. Clin. Dev. Immunol. 2012, 962702 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"31_CR217","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","volume":"221","author":"Z Prohaszka","year":"2016","unstructured":"Prohaszka, Z., Nilsson, B., Frazer-Abel, A. & Kirschfink, M. Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology 221, 1247\u20131258 (2016).","journal-title":"Immunobiology"},{"key":"31_CR218","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.40747","volume":"71","author":"AHJ Kim","year":"2019","unstructured":"Kim, A. H. J. et al. Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol. 71, 420\u2013430 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"31_CR219","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2018.09.027","volume":"95","author":"HR Wilson","year":"2019","unstructured":"Wilson, H. R. et al. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney Int. 95, 655\u2013665 (2019).","journal-title":"Kidney Int."},{"key":"31_CR220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2018.02.004","volume":"456","author":"AJF Thielen","year":"2018","unstructured":"Thielen, A. J. F. et al. CRISPR\/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research. J. Immunol. Methods 456, 15\u201322 (2018).","journal-title":"J. Immunol. Methods"},{"key":"31_CR221","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.it.2016.12.001","volume":"38","author":"KE Neu","year":"2017","unstructured":"Neu, K. E., Tang, Q., Wilson, P. C. & Khan, A. A. Single-cell genomics: approaches and utility in immunology. Trends Immunol. 38, 140\u2013149 (2017).","journal-title":"Trends Immunol."},{"key":"31_CR222","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.aao4988","volume":"359","author":"D Ugurlar","year":"2018","unstructured":"Ugurlar, D. et al. Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science 359, 794\u2013797 (2018).","journal-title":"Science"},{"key":"31_CR223","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/nm.2543","volume":"17","author":"Q Wang","year":"2011","unstructured":"Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 17, 1674\u20131679 (2011).","journal-title":"Nat. Med."},{"key":"31_CR224","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molcel.2016.05.016","volume":"63","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol. Cell 63, 135\u2013145 (2016).","journal-title":"Mol. Cell"},{"key":"31_CR225","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1073\/pnas.1616998114","volume":"114","author":"SA Mortensen","year":"2017","unstructured":"Mortensen, S. A. et al. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proc. Natl Acad. Sci. USA 114, 986\u2013991 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR226","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260\u20131263 (2014). This study revealed the structural basis of C1q-mediated classical pathway activation on antibody-targeted surfaces and paved the way for the clinical development of HexaBodies.","journal-title":"Science"},{"key":"31_CR227","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.4049\/jimmunol.1600648","volume":"197","author":"EM Cook","year":"2016","unstructured":"Cook, E. M. et al. Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J. Immunol. 197, 1762\u20131775 (2016).","journal-title":"J. Immunol."},{"key":"31_CR228","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03576131\n\n (2019)."},{"key":"31_CR229","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","volume":"48","author":"TM Woodruff","year":"2011","unstructured":"Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631\u20131642 (2011).","journal-title":"Mol. Immunol."},{"key":"31_CR230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41594-018-0067-z","volume":"25","author":"H Liu","year":"2018","unstructured":"Liu, H. et al. Orthosteric and allosteric action of the C5a receptor antagonists. Nat. Struct. Mol. Biol. 25, 472\u2013481 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"31_CR231","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.immuni.2013.10.018","volume":"39","author":"MK Liszewski","year":"2013","unstructured":"Liszewski, M. K. et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39, 1143\u20131157 (2013).","journal-title":"Immunity"},{"key":"31_CR232","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/imr.12472","volume":"274","author":"S Freeley","year":"2016","unstructured":"Freeley, S., Kemper, C. & Le, F. G. The \u2018ins and outs\u2019 of complement-driven immune responses. Immunol. Rev. 274, 16\u201332 (2016).","journal-title":"Immunol. Rev."},{"key":"31_CR233","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aaw1280","volume":"363","author":"RI Amann","year":"2019","unstructured":"Amann, R. I. et al. Toward unrestricted use of public genomic data. Science 363, 350\u2013352 (2019).","journal-title":"Science"},{"key":"31_CR234","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436\u2013444 (2008).","journal-title":"Nature"},{"key":"31_CR235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.semcdb.2017.11.023","volume":"85","author":"D Ajona","year":"2019","unstructured":"Ajona, D., Ortiz-Espinosa, S. & Pio, R. Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment. Semin. Cell Dev. Biol. 85, 153\u2013163 (2019).","journal-title":"Semin. Cell Dev. Biol."},{"key":"31_CR236","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski, M. M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225\u20131235 (2008).","journal-title":"Nat. Immunol."},{"key":"31_CR237","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccell.2018.09.003","volume":"34","author":"TR Medler","year":"2018","unstructured":"Medler, T. R. et al. Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell 34, 561\u2013578 (2018).","journal-title":"Cancer Cell"},{"key":"31_CR238","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","volume":"7","author":"D Ajona","year":"2017","unstructured":"Ajona, D. et al. A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 7, 694\u2013703 (2017). This study highlights the translational potential of combining targeted complement C5aR1 inhibition with other immunomodulatory therapies in cancer.","journal-title":"Cancer Discov."},{"key":"31_CR239","volume":"6","author":"H Zha","year":"2017","unstructured":"Zha, H. et al. Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1\/PD-L1 blockade. Oncoimmunology 6, e1349587 (2017).","journal-title":"Oncoimmunology"},{"key":"31_CR240","unstructured":"US National Library of Medicine. ClinicalTrials.gov \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03665129\n\n (2019)."},{"key":"31_CR241","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122311","volume":"4","author":"KL Singel","year":"2019","unstructured":"Singel, K. L. et al. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight 4, e122311 (2019).","journal-title":"JCI Insight"},{"key":"31_CR242","doi-asserted-by":"crossref","first-page":"eaaf6295","DOI":"10.1126\/scitranslmed.aaf6295","volume":"9","author":"Q Shi","year":"2017","unstructured":"Shi, Q. et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci. Transl Med. 9, eaaf6295 (2017).","journal-title":"Sci. Transl Med."},{"key":"31_CR243","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic, B. et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 100, 1322\u20131336 (2018).","journal-title":"Neuron"},{"key":"31_CR244","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","volume":"274","author":"P Nytrova","year":"2014","unstructured":"Nytrova, P. et al. Complement activation in patients with neuromyelitis optica. J. Neuroimmunol. 274, 185\u2013191 (2014).","journal-title":"J. Neuroimmunol."},{"key":"31_CR245","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1073\/pnas.1111924109","volume":"109","author":"V Ramaglia","year":"2012","unstructured":"Ramaglia, V. et al. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc. Natl Acad. Sci. USA 109, 965\u2013970 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31_CR246","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","volume":"183","author":"MI Fonseca","year":"2009","unstructured":"Fonseca, M. I. et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer\u2019s disease. J. Immunol. 183, 1375\u20131383 (2009).","journal-title":"J. Immunol."},{"key":"31_CR247","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bph.13730","volume":"174","author":"JD Lee","year":"2017","unstructured":"Lee, J. D. et al. Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 174, 689\u2013699 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"31_CR248","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.4049\/jimmunol.181.12.8727","volume":"181","author":"TM Woodruff","year":"2008","unstructured":"Woodruff, T. M. et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 181, 8727\u20138734 (2008).","journal-title":"J. Immunol."},{"key":"31_CR249","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock, S. J. et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 12, 554\u2013562 (2013).","journal-title":"Lancet Neurol."},{"key":"31_CR250","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/sj.emboj.7601004","volume":"25","author":"Y Rahpeymai","year":"2006","unstructured":"Rahpeymai, Y. et al. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 25, 1364\u20131374 (2006).","journal-title":"EMBO J."},{"key":"31_CR251","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tins.2018.03.009","volume":"41","author":"LG Coulthard","year":"2018","unstructured":"Coulthard, L. G., Hawksworth, O. A. & Woodruff, T. M. Complement: the emerging architect of the developing brain. Trends Neurosci. 41, 373\u2013384 (2018).","journal-title":"Trends Neurosci."},{"key":"31_CR252","unstructured":"Orphanet. About rare diseases. Orphanet \nhttps:\/\/www.orpha.net\/consor\/cgi-bin\/Education_AboutRareDiseases.php\n\n (2012)."},{"key":"31_CR253","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","volume":"392","author":"L Luzzatto","year":"2018","unstructured":"Luzzatto, L. et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet 392, 791\u2013794 (2018). This opinion article raises awareness about the exuberant costs of orphan drugs in clinical practice and points to the adoption of new guidelines and regulations for orphan drug development.","journal-title":"Lancet"},{"key":"31_CR254","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-74","volume":"7","author":"W Hughes-Wilson","year":"2012","unstructured":"Hughes-Wilson, W., Palma, A., Schuurman, A. & Simoens, S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J. Rare Dis. 7, 74 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"31_CR255","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(15)60297-5","volume":"385","author":"L Luzzatto","year":"2015","unstructured":"Luzzatto, L. et al. Rare diseases and effective treatments: are we delivering? Lancet 385, 750\u2013752 (2015).","journal-title":"Lancet"},{"key":"31_CR256","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1500848","volume":"372","author":"J Avorn","year":"2015","unstructured":"Avorn, J. The $2.6 billion pill \u2014 methodologic and policy considerations. N. Engl. J. Med. 372, 1877\u20131879 (2015).","journal-title":"N. Engl. J. Med."},{"key":"31_CR257","volume":"345","author":"AF Shaughnessy","year":"2012","unstructured":"Shaughnessy, A. F. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 345, e8346 (2012).","journal-title":"BMJ"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0031-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:44:53Z","timestamp":1684619093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-019-0031-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":257,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1038\/s41573-019-0031-6","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"13 June 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes. J.D.L. and D.R. are inventors of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. J.D.L. is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (that is, 4(1MeW)7W\/POT-4\/APL-1 and PEGylated derivatives). D.C.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}